Table 1 Clinical, virological and immunological characteristics for individuals included in the study
Population with age group | nr | Age range (mean) | CD4 cells/μl (range) | CD8 cells/μl (range) | CD4:CD8 ratio | Virus load copies/ml (range) | Length of ART months (range) |
|---|---|---|---|---|---|---|---|
Control < =30 | 27 | 21-30 (25.85) | ND | ND | 1.00 (0.41-1.84) | NA | NA |
Non-treated < =30 | 14 | 23-30 (25.36) | 628 (394-1096) | 1188 (630-2096) | 0.61 (0.23-1.19) | 102070 (20-1×106) | NA |
Treated < =30 | 18 | 21-30 (25.61) | 580 (308-1169) | 862 (307-1567) | 0.68 (0.32-1.33) | 156 (0-893) | 9.2 (1-48) |
Control 31 = <<=50 | 38 | 31-50 (39.97) | ND | ND | 1.93 (0.23-5.47) | NA | NA |
Non-treated 31 = <<=50 | 10 | 31-47 (38.30) | 559 (278-1357) | 985 (421-1762) | 0.7 (0.19-2.03) | 33132 (233-1.3×105) | NA |
Treated 31 = <<=50 | 24 | 31-50 (41.88) | 589 (222-2010) | 884 (322-2175) | 0.79 (0.15-1.96) | 6 (0-36) | 74.1 (2-160) |
Control > =51 | 36 | 51-87 (58.83) | ND | ND | 2.12 (0.88-5.17) | NA | NA |
Non-treated > =51 | 11 | 51-85 (64.36) | 604 (336-1235) | 1334 (613-3185) | 0.51 (0.16-0.92) | 39886 (0-1.2×105) | NA |
Treated > =51 | 28 | 51-76 (57.46) | 599 (247-1412) | 895 (473-1452) | 0.74 (0.20-2.99) | 25.2 (0-343) | 64.1 (2-163) |